Evidence map›Paper›PMID 42088618›Full record

ArticleMolecular therapy. Oncology2026

Non-viral targeted integration at the CISH locus enables CAR-NK cell engineering with enhanced anti-tumor activity.

Jiao Wang, Yao Sun, Jakob Starzyk, Fei Wang, Xin Dong, Richard Shan, Xuemei He, Keqiang Xie, Guozhu Xie, Hao Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jiao WangFull Circles Therapeutics, Inc. 625 Mt. Auburn St., Ste. 105, Cambridge, MA 02138, USA.
Yao SunDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Jakob StarzykFull Circles Therapeutics, Inc. 625 Mt. Auburn St., Ste. 105, Cambridge, MA 02138, USA.
Fei WangDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Xin DongDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Richard ShanFull Circles Therapeutics, Inc. 625 Mt. Auburn St., Ste. 105, Cambridge, MA 02138, USA.
Xuemei HeFull Circles Therapeutics, Inc. 625 Mt. Auburn St., Ste. 105, Cambridge, MA 02138, USA.
Keqiang XieFull Circles Therapeutics, Inc. 625 Mt. Auburn St., Ste. 105, Cambridge, MA 02138, USA.
Guozhu XieDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Hao WuFull Circles Therapeutics, Inc. 625 Mt. Auburn St., Ste. 105, Cambridge, MA 02138, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural killer (NK) cells hold promise for adoptive cell therapy due to their innate cytotoxicity. Early clinical trials confirm their safety and efficacy in cancer and autoimmune disease treatment. Engineering NK cells with chimeric antigen receptors (CARs) enhances target specificity and facilitates their development as off-the-shelf allogeneic therapies. However, both viral and non-viral engineering methods of NK cells present challenges. Here, we introduce

Indexed as

allogeneic cell therapycircular single-stranded DNACISHCLICKMT: Regular Issuenon-viral CAR NK

Identifiers

PMID42088618
PMCPMC13137893

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.